Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy

Virology Journal

Volumn 4, Issue , 2007, Pages

  Han, Tie ^a   Tang, Yizhe ^a   Ugai, Hideyo ^a   Perry, Leslie E ^a   Siegal, Gene P ^a   Contreras, Juan L ^a   Wu, Hongju ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; EPITOPE; TRANSACTIVATOR PROTEIN; CAPSID PROTEIN; CAR RECEPTOR; HEXON CAPSID PROTEIN, ADENOVIRUS; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ADENOVIRUS 5; ARTICLE; CELL LINE; CELL SURFACE; COMPETITIVE INHIBITION; FLUORESCENCE; GENE TARGETING; GENE TRANSFER; GLIOMA CELL; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; NONHUMAN; TARGET CELL; ANIMAL; ANTIBODY SPECIFICITY; CANCER TRANSPLANTATION; CHEMISTRY; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; GLIOMA; HUMAN; HUMAN ADENOVIRUS; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE;

ADENOVIRIDAE; HUMAN ADENOVIRUS;

ADENOVIRUSES, HUMAN; AMINO ACID MOTIFS; ANIMALS; CAPSID PROTEINS; CELL LINE; GENE PRODUCTS, TAT; GENE THERAPY; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGAN SPECIFICITY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC;

EID: 37249058543     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-103     Document Type: Article

References (55)

1. Transductional targeting of adenovirus vectors for gene therapy. JN Glasgow M Everts DT Curiel, Cancer Gene Ther 2006 13 9 830 844 16439993 10.1038/sj.cgt.7700928
2. Targeted and shielded adenovectors for cancer therapy. SJ Hedley J Chen JD Mountz J Li DT Curiel N Korokhov I Kovesdi, Cancer Immunol Immunother 2006 55 11 1412 1419 10.1007/s00262-006-0158-2 16612598
3. Current developments in adenovirus-based cancer gene therapy. DT Rein M Breidenbach DT Curiel, Future Oncol 2006 2 1 137 143 16556080 10.2217/14796694.2.1.137
4. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. M Bai B Harfe P Freimuth, J Virol 1993 67 9 5198 5205 8350395
5. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. JM Bergelson JA Cunningham G Droguett EA Kurt-Jones A Krithivas JS Hong MS Horwitz RL Crowell RW Finberg, Science 1997 275 5304 1320 1323 10.1126/science.275.5304.1320 9036860
6. Cell-binding domain of adenovirus serotype 2 fiber. N Louis P Fender A Barge P Kitts J Chroboczek, J Virol 1994 68 6 4104 4106 8189552
7. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. TJ Wickham P Mathias DA Cheresh GR Nemerow, Cell 1993 73 2 309 319 10.1016/0092-8674(93)90231-E 8477447
8. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. I Dmitriev E Kashentseva BE Rogers V Krasnykh DT Curiel, J Virol 2000 74 15 6875 6884 10888627 10.1128/JVI.74.15.6875-6884.2000
9. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. HJ Li M Everts L Pereboeva S Komarova A Idan DT Curiel HR Herschman, Cancer Res 2007 67 11 5354 5361 10.1158/0008-5472.CAN-06-4679 17545616
10. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Y Tang T Han M Everts ZB Zhu GY Gillespie DT Curiel H Wu, Gene Ther 2007 14 6 523 532 10.1038/sj.gt.3302888 17167498
11. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. SJ Watkins VV Mesyanzhinov LP Kurochkina RE Hawkins, Gene Ther 1997 4 10 1004 1012 10.1038/sj.gt.3300511 9415305
12. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. N Belousova V Krendelchtchikova DT Curiel V Krasnykh, J Virol 2002 76 17 8621 8631 12163581 10.1128/JVI.76.17.8621-8631.2002
13. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. I Dmitriev V Krasnykh CR Miller M Wang E Kashentseva G Mikheeva N Belousova DT Curiel, J Virol 1998 72 12 9706 9713 9811704
14. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. TJ Wickham PW Roelvink DE Brough I Kovesdi, Nat Biotechnol 1996 14 11 1570 1573 10.1038/nbt1196-1570 9634823
15. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. H Wu T Seki I Dmitriev T Uil E Kashentseva T Han DT Curiel, Hum Gene Ther 2002 13 13 1647 1653 10.1089/10430340260201734 12228019
16. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. S Deshayes MC Morris G Divita F Heitz, Cell Mol Life Sci 2005 62 16 1839 1849 10.1007/s00018-005-5109-0 15968462
17. Transcellular protein transduction using the Tat protein of HIV-1. A Fittipaldi M Giacca, Adv Drug Deliv Rev 2005 57 4 597 608 10.1016/j.addr.2004. 10.011 15722166
18. Transduction peptides: from technology to physiology. A Joliot A Prochiantz, Nat Cell Biol 2004 6 3 189 196 10.1038/ncb0304-189 15039791
19. Cell penetrating peptides in drug delivery. EL Snyder SF Dowdy, Pharm Res 2004 21 3 389 393 10.1023/B:PHAM.0000019289.61978.f5 15070086
20. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. JS Wadia SF Dowdy, Adv Drug Deliv Rev 2005 57 4 579 596 10.1016/j.addr.2004.10.005 15722165
21. Structural and functional characterization of human immunodeficiency virus tat protein. S Ruben A Perkins R Purcell K Joung R Sia R Burghoff WA Haseltine CA Rosen, J Virol 1989 63 1 1 8 2535718
22. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. E Vives P Brodin B Lebleu, J Biol Chem 1997 272 25 16010 16017 10.1074/jbc.272.25.16010 9188504
23. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. A Ferrari V Pellegrini C Arcangeli A Fittipaldi M Giacca F Beltram, Mol Ther 2003 8 2 284 294 10.1016/S1525-0016(03) 00122-9 12907151
24. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. R Fischer K Kohler M Fotin-Mleczek R Brock, J Biol Chem 2004 279 13 12625 12635 10.1074/jbc.M311461200 14707144
25. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. A Fittipaldi A Ferrari M Zoppe C Arcangeli V Pellegrini F Beltram M Giacca, J Biol Chem 2003 278 36 34141 34149 10.1074/jbc.M303045200 12773529
26. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. JP Richard K Melikov E Vives C Ramos B Verbeure MJ Gait LV Chernomordik B Lebleu, J Biol Chem 2003 278 1 585 590 10.1074/jbc.M209548200 12411431
27. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. M Tyagi M Rusnati M Presta M Giacca, J Biol Chem 2001 276 5 3254 3261 10.1074/jbc.M006701200 11024024
28. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. M Maccarana B Casu U Lindahl, J Biol Chem 1993 268 32 23898 23905 8226930
29. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. M Rusnati G Tulipano D Spillmann E Tanghetti P Oreste G Zoppetti M Giacca M Presta, J Biol Chem 1999 274 40 28198 28205 10.1074/jbc.274.40.28198 10497173
30. Defining the interleukin-8-binding domain of heparan sulfate. D Spillmann D Witt U Lindahl, J Biol Chem 1998 273 25 15487 15493 10.1074/jbc.273.25.15487 9624135
31. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. H Nagahara AM Vocero-Akbani EL Snyder A Ho DG Latham NA Lissy M Becker-Hapak SA Ezhevsky SF Dowdy, Nat Med 1998 4 12 1449 1452 10.1038/4042 9846587
32. Protection against ischemic brain injury by protein therapeutics. S Asoh I Ohsawa T Mori K Katsura T Hiraide Y Katayama M Kimura D Ozaki K Yamagata S Ohta, Proc Natl Acad Sci U S A 2002 99 26 17107 17112 12475933 10.1073/pnas.262460299
33. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. G Cao W Pei H Ge Q Liang Y Luo FR Sharp A Lu R Ran SH Graham J Chen, J Neurosci 2002 22 13 5423 5431 12097494
34. Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. KO Orii JH Grubb C Vogler B Levy Y Tan K Markova BL Davidson Q Mao T Orii N Kondo WS Sly, Mol Ther 2005 12 2 345 352 10.1016/j.ymthe.2005.02.031 16043103
35. In vivo protein transduction: delivery of a biologically active protein into the mouse. SR Schwarze A Ho A Vocero-Akbani SF Dowdy, Science 1999 285 5433 1569 1572 10.1126/science.285.5433.1569 10477521
36. Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. A Eguchi T Akuta H Okuyama T Senda H Yokoi H Inokuchi S Fujita T Hayakawa K Takeda M Hasegawa M Nakanishi, J Biol Chem 2001 276 28 26204 26210 10.1074/jbc.M010625200 11346640
37. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. JP Gratton J Yu JW Griffith RW Babbitt RS Scotland R Hickey FJ Giordano WC Sessa, Nat Med 2003 9 3 357 362 10.1038/nm835 12598894
38. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. IA Ignatovich EB Dizhe AV Pavlotskaya BN Akifiev SV Burov SV Orlov AP Perevozchikov, J Biol Chem 2003 278 43 42625 42636 10.1074/jbc.M301431200 12882958
39. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. M Lewin N Carlesso CH Tung XW Tang D Cory DT Scadden R Weissleder, Nat Biotechnol 2000 18 4 410 414 10.1038/74464 10748521
40. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. S Sandgren F Cheng M Belting, J Biol Chem 2002 277 41 38877 38883 10.1074/jbc.M205395200 12163493
41. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. VP Torchilin R Rammohan V Weissig TS Levchenko, Proc Natl Acad Sci U S A 2001 98 15 8786 8791 11438707 10.1073/pnas.151247498
42. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. F Kuhnel B Schulte T Wirth N Woller S Schafers L Zender M Manns S Kubicka, J Virol 2004 78 24 13743 13754 15564483 10.1128/JVI.78.24.13743-13754.2004
43. Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. T Seki I Dmitriev K Suzuki E Kashentseva K Takayama M Rots T Uil H Wu M Wang DT Curiel, Gene Ther 2002 9 16 1101 1108 10.1038/sj.gt.3301815 12140738
44. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. WJ Van Houdt H Wu JN Glasgow ML Lamfers CM Dirven GY Gillespie DT Curiel YS Haviv, Neuro Oncol 2007 9 3 280 290 10.1215/15228517-2007-017 17522331
45. A TAT-streptavidin fusion protein directs uptake of biotinylated cargo into mammalian cells. B Albarran R To PS Stayton, Protein Eng Des Sel 2005 18 3 147 152 10.1093/protein/gzi014 15820981
46. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. S Al-Taei NA Penning JC Simpson S Futaki T Takeuchi I Nakase AT Jones, Bioconjug Chem 2006 17 1 90 100 10.1021/bc050274h 16417256
47. A ubiquitin-based assay for the cytosolic uptake of protein transduction domains. F Loison P Nizard T Sourisseau P Le Goff L Debure Y Le Drean D Michel, Mol Ther 2005 11 2 205 214 10.1016/j.ymthe.2004.10.010 15668132
48. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. JS Wadia RV Stan SF Dowdy, Nat Med 2004 10 3 310 315 10.1038/nm996 14770178
49. Heparan sulfate proteoglycans and cancer. FH Blackhall CL Merry EJ Davies GC Jayson, Br J Cancer 2001 85 8 1094 1098 10.1054/bjoc.2001.2054 11710818
50. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. EJ Davies FH Blackhall JH Shanks G David AT McGown R Swindell RJ Slade P Martin-Hirsch JT Gallagher GC Jayson, Clin Cancer Res 2004 10 15 5178 5186 10.1158/1078-0432.CCR-03-0103 15297422
51. Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. PA Steck RP Moser JM Bruner L Liang AN Freidman TL Hwang WK Yung, Cancer Res 1989 49 8 2096 2103 2522816
52. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. A Kanerva GV Mikheeva V Krasnykh CJ Coolidge JT Lam PJ Mahasreshti SD Barker M Straughn MN Barnes RD Alvarez A Hemminki DT Curiel, Clin Cancer Res 2002 8 1 275 280 11801569
53. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. H Wu I Dmitriev E Kashentseva T Seki M Wang DT Curiel, J Virol 2002 76 24 12775 12782 12438602 10.1128/JVI.76.24.12775-12782.2002
54. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. JN Glasgow EJ Kremer A Hemminki GP Siegal JT Douglas DT Curiel, Virology 2004 324 1 103 116 10.1016/j.virol.2004.03.028 15183058
55. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. LP Le HN Le IP Dmitriev JG Davydova T Gavrikova S Yamamoto DT Curiel M Yamamoto, J Natl Cancer Inst 2006 98 3 203 214 16449680